Tvardi Therapeutics, Inc. (TVRD) stock
TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.04+0.03 (+2.97%)
Close on Nov 18, 2026Market cap $13.87MP/E –Yield 0.00%
Tvardi Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Tvardi Therapeutics's revenue for the twelve months ending Mar 31, 2025 was $7.57M, down 55.3% year over year. For fiscal 2024 it was $7.14M, down 66.0% from the year before. Over ten years it grew 8.4% a year on average. The highest annual figure on record is $135.08M in fiscal 2020.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.14M | -66.0% |
| FY2023 | Dec 31, 2023 | $20.97M | -49.9% |
| FY2022 | Dec 31, 2022 | $41.87M | +81.8% |
| FY2021 | Dec 31, 2021 | $23.03M | -83.0% |
| FY2020 | Dec 31, 2020 | $135.08M | +579.3% |
| FY2019 | Dec 31, 2019 | $19.89M | +47.6% |
| FY2018 | Dec 31, 2018 | $13.47M | +1378.5% |
| FY2017 | Dec 31, 2017 | $911.00K | +959.3% |
| FY2016 | Dec 31, 2016 | $86.00K | -97.7% |
| FY2015 | Dec 31, 2015 | $3.80M | +19.7% |
| FY2014 | Dec 31, 2014 | $3.18M | -73.4% |
| FY2013 | Dec 31, 2013 | $11.96M | +905.4% |
| FY2012 | Dec 31, 2012 | $1.19M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | $2.57M | +20.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.46M | -51.6% |
| Q3 FY2024 | Sep 30, 2024 | $2.56M | -47.5% |
| Q2 FY2024 | Jun 30, 2024 | $991.00K | -85.7% |
| Q1 FY2024 | Mar 31, 2024 | $2.14M | -65.4% |
| Q4 FY2023 | Dec 31, 2023 | $3.00M | -7.9% |
| Q3 FY2023 | Sep 30, 2023 | $4.87M | -55.0% |
| Q2 FY2023 | Jun 30, 2023 | $6.93M | -69.9% |
| Q1 FY2023 | Mar 31, 2023 | $6.17M | +28.7% |
| Q4 FY2022 | Dec 31, 2022 | $3.26M | +297.2% |
| Q3 FY2022 | Sep 30, 2022 | $10.81M | -46.7% |
| Q2 FY2022 | Jun 30, 2022 | $23.00M | – |
| Q1 FY2022 | Mar 31, 2022 | $4.79M | +147.5% |
| Q4 FY2021 | Dec 31, 2021 | $821.00K | -99.3% |
| Q3 FY2021 | Sep 30, 2021 | $20.27M | +118.8% |
| Q2 FY2021 | Jun 30, 2021 | $0 | -100.0% |
| Q1 FY2021 | Mar 31, 2021 | $1.94M | -76.1% |
| Q4 FY2020 | Dec 31, 2020 | $112.09M | +2384.8% |
| Q3 FY2020 | Sep 30, 2020 | $9.27M | +60.2% |
| Q2 FY2020 | Jun 30, 2020 | $5.63M | +8.2% |
| Q1 FY2020 | Mar 31, 2020 | $8.09M | +84.7% |
| Q4 FY2019 | Dec 31, 2019 | $4.51M | -18.5% |
| Q3 FY2019 | Sep 30, 2019 | $5.79M | +14.3% |
| Q2 FY2019 | Jun 30, 2019 | $5.21M | +81.2% |
| Q1 FY2019 | Mar 31, 2019 | $4.38M | – |
| Q4 FY2018 | Dec 31, 2018 | $5.53M | – |
| Q3 FY2018 | Sep 30, 2018 | $5.06M | – |
| Q2 FY2018 | Jun 30, 2018 | $2.87M | +215.5% |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
| Q3 FY2017 | Sep 30, 2017 | $0 | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
| Q1 FY2017 | Mar 31, 2017 | $911.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $0 | – |
| Q3 FY2016 | Sep 30, 2016 | $0 | – |
See a number that looks wrong?